The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Multimodal therapy and resectability in lung cancer
Yannis Perentes, MD, PhD, University of Lausanne, Lausanne, Switzerland,
discusses the evidence outlining benefit to a multimodal approach to lung
cancer treatment, utilising chemotherapy, immunotherapy (IO) in neoadjuvant
and adjuvant settings in resectable patients. Current clinical trials investigate
treatment options in borderline or unresectable patients. The AEGEAN trial
(NCT05925530) assesses chemo-IO induction before definitive localised
treatments to understand the resectability and inform on future treatment of
these patients. This interview took place at the BTOG 2025 congress in Belfast,
UK.
These works are owned by Magdalen Medical Publishing (MMP) and are
protected by copyright laws and treaties around the world. All rights are
reserved.
